crackdown on glp 1 meds The FDA is cracking down ‘misleading’ compounded GLP-1s from telehealth companies., Compounded weight loss drugs are not FDA-approved, which means the agency does not review their safety, The supply of GLP-1 drugs

While MT2 has a broad spectrum of action, PT-141 targets a specific area

Peptide amount in the vial Desired peptide amount Bacteriostatic water RESULT Mark on the syringe: 10 units Your solution is 10 mg per 1 ml

Then you'll see your doctor at regular intervals so they can monitor you for side effects, track your progress, and monitor for any potential adverse effects

Roth, A

Potential candidates for off-label use: Clinicians may consider GLP-1 therapy for women with PCOS who meet the following criteria: Overweight or obesity (particularly BMI 30 kg/m) with PCOS Insulin resistance or impaired glucose tolerance Inadequate response to lifestyle modification and other treatments No contraindications to GLP-1 therapy Not planning pregnancy in the immediate future Contraindications and precautions: GLP-1 receptor agonists are contraindicated in pregnancy and breastfeeding

Lupus patients on corticosteroids often have disproportionate visceral fat even at lower body weights, and tracking composition changes is more informative than tracking weight alone